MTDMettler Toledo

$1,550.83+20% 1Y

$1,550.83

$1.0K52 weeks$1.6K

Is the price fair?

Fair

Neither cheap nor expensive: growth expectations in line with delivery and in its normal P/E range.

1 neutral, 2 without data

What the price assumes~+10% a yearderived · Jun 30, 2026

Priced for ~10% a year FCF growth. Moderate growth expectations are priced in.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 34.9 vs a 35.2 median over 41 quarters (−1% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 75% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Mettler Toledo trades at 34.9× earnings against 35.2× for the median Diagnostics & Research name, cheaper than its own group.

34.9

Trailing P/E · Diagnostics & Research median 35.2 · cheaper than the typical name in its group

Price / sales: 5.60
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 3.7%
Free cash flow yield · Diagnostics & Research median 3.7%
Growth the price implies: +9.5%
Growth the price implies · The price pays for +9.5% free cash flow growth a year for a decade; the business has delivered +0.22% a year over the last three.

Details›

What the market has paid for these earnings: 41 quarters of its own multiple × $44.38 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$1,359.65
Its own P/E history, median	$1,563.31
Its own P/E history, upper quartile	$1,733.94
52-week range	$1,025.53 – $1,550.83
Today	$1,550.83

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

The closest names by size in the same industry